Recent BioUtah News & Events

SALT LAKE CITY, JANUARY 15, 2026—SPARC Health, a collaborative effort between Park City Angels (PCA), BioUtah, BioHive, in partnership with Governor’s Office of Economic Opportunity (GOEO), today announced applications are now open for its second cohort program. The announcement celebrates the impressive achievements of the inaugural cohort and the growing momentum of Utah’s healthcare innovation […]

3 Key takeaways   Participants gain a rare platform to pitch to a specialized panel of judges who possess the deep industry expertise required to fund and scale complex medical technologies, pharmaceuticals, and digital health solutions. Following in March, after the global JPMorgan Healthcare Conference, participating companies can take the “JPM momentum” and apply it […]

The purchase is expected to expand Haemonetics’ impact in fast-growing markets for structural heart and endovascular procedures.

State-of-the-art, multi-modality breast biopsy system slated to be in the market in early 2026

DiscGenics Treats First Patient in Phase 3 Clinical Trial of IDCT (Rebonuputemcel) for Symptomatic Mild-to-Moderate Lumbar Degenerative Disc Disease

Published in the journal PREGNANCY, the PRIME Study demonstrates significant improvements in neonatal outcomes with early risk screening and targeted interventions.

Fluidx GPX Embolic Device Pivotal Trial Completes Enrollment

Dr. Mark Davis, discoverer of the first T-cell receptor genes and Stanford Professor, to advise the Company on immunological strategies for its novel cancer treatment platform.

Wasatch BioLabs Announces Co-Marketing Agreement With Agilent to Advance Native-Read Targeted Sequencing

As we look back at 2025, we’re thankful for the progress our team and partners helped drive this year.

The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)

2025 marked a year of significant progress of reached milestones and successes for Bloom Surgical

A microbiologist, Adam Barker, PhD, was ARUP’s chief scientific officer and director of Research and Development before being named chief operations officer—now adds Reference Business Unit president to his title.

The Australian patent represents the first patent granted for the Company’s new point-of-care testing platform.

Merit Medical’s Fred Lampropoulos Honored by Nasdaq

Perimeter Solutions Announces Agreement to Acquire MMT for $685 Million

Freyya Recognized at Transatlantic Angel Competition (TAAC8)

Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India

Collaboration expands Owlet’s national DME footprint, strengthens access for Medicaid and TRICARE families, and supports continued growth in prescription-backed revenue channel.

In-vitro studies confirmed strong uptake of cell-targeting nanoparticles by cancer cells and strong activation of Smart mRNAs inside cancer cells

Peel Therapeutics CEO Joshua Schiffman Presents at CureCRC Summit

Ratio Therapeutics has Successfully Dosed the First Cohort in its Phase 1/2 Study Evaluating a Novel FAP-Targeted Radiopharmaceutical in Patients with Late-Stage Aggressive Sarcomas

Investors Buy up Stocks in Biggest Follow-on Offering Day in Biotech History

Talent Ready Utah Calling for Innovator Input

TGA approval enables regional launch of Owlet’s clinically validated, award-winning infant health monitor; Owlet360™ subscription marks first international expansion of the Company’s recurring-revenue platform.

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12).

New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement.

FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8.

Prestigious recognition validates Canary Speech’s leadership in healthcare-focused AI voice technology and its proven interoperability with the Microsoft Cloud

bioMérieux Celebrates New Regional Headquarters in Riyadh, Saudi Arabia

PolarityBio thanks the clinical trial sites and, most importantly, the participants, for making this milestone in DFU biologic therapy development possible